Reaction
Central Nervous System Infection reporting signals
As of the last recalculation, Central Nervous System Infection appears in 1,128 FAERS reports alongside 24 co-occurring drug terms. The strongest observed disproportionality signal is ADO-TRASTUZUMAB EMTANSINE (PRR 35.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ado-Trastuzumab Emtansine | 16 | 35.5 | 35.6 |
| Dexamethasone Sodium Phosphate | 12 | 22.0 | 22.0 |
| Basiliximab | 13 | 20.6 | 20.6 |
| Pegaspargase | 13 | 19.8 | 19.8 |
| Micafungin Sodium | 9 | 19.7 | 19.8 |
| Tacrolimus Ointment 0.1% | 109 | 17.8 | 17.8 |
| Tacrolimus Extended-Release Capsules | 109 | 17.7 | 17.7 |
| Posaconazole Delayed-Release | 10 | 16.9 | 17.0 |
| Tacrolimus | 114 | 14.8 | 14.8 |
| Mycophenolate Mofetil | 98 | 14.5 | 14.5 |
| Mycophenolate Mofetil Hydrochloride | 98 | 14.5 | 14.5 |
| Fludarabine Phosphate | 28 | 13.4 | 13.5 |
| Amphotericin B | 9 | 13.4 | 13.4 |
| Posaconazole | 11 | 12.6 | 12.6 |
| Phenytoin | 14 | 12.5 | 12.5 |
| Cytarabine | 39 | 12.4 | 12.4 |
| Axicabtagene Ciloleucel | 6 | 11.3 | 11.3 |
| Voriconazole Injection | 13 | 11.2 | 11.2 |
| Rifampin | 8 | 10.2 | 10.2 |
| Pyrazinamide | 5 | 9.9 | 9.9 |
| Temozolomide | 11 | 9.7 | 9.7 |
| Doxorubicin Hydrochloride | 14 | 8.0 | 8.0 |
| Blinatumomab | 4 | 7.1 | 7.1 |
| Ocrelizumab | 21 | 6.3 | 6.3 |